Insight Molecular Diagnostics outlines transplant testing strategy in investor presentation

PUBT · 2d ago
Insight Molecular Diagnostics outlines transplant testing strategy in investor presentation
  • Insight Molecular Diagnostics investor presentation outlined a strategy to decentralize molecular diagnostics by selling kitted assays for in-house hospital lab testing.
  • Transplant rejection testing positioned as the near-term priority, centered on the GraftAssureDx program, with RUO kits launched in 2024.
  • FDA IVD submission for clinical use filed in March 2026; FDA clearance for kidney on Bio-Rad’s QX600Dx targeted in 2026.
  • Medicare reimbursement cited at $2,753 per result for GraftAssureCore under CPT 81479 and DEX Z-code Z0507.
  • Management estimated regulated transplant testing as a ~$3B global opportunity, with U.S. kidney baseline TAM at $500 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.